0001209191-18-019687.txt : 20180314
0001209191-18-019687.hdr.sgml : 20180314
20180314201327
ACCESSION NUMBER: 0001209191-18-019687
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180312
FILED AS OF DATE: 20180314
DATE AS OF CHANGE: 20180314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PELLETIER SAUNDRA L
CENTRAL INDEX KEY: 0001251371
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36754
FILM NUMBER: 18690757
MAIL ADDRESS:
STREET 1: C/O EVOFEM BIOSCIENCES, INC.
STREET 2: 12400 HIGH BLUFF DRIVE, SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Evofem Biosciences, Inc.
CENTRAL INDEX KEY: 0001618835
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208527075
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 550-1900
MAIL ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Neothetics, Inc.
DATE OF NAME CHANGE: 20140905
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-12
0
0001618835
Evofem Biosciences, Inc.
EVFM
0001251371
PELLETIER SAUNDRA L
C/O EVOFEM BIOSCIENCES, INC.
12400 HIGH BLUFF DRIVE, SUITE 600
SAN DIEGO
CA
92130
1
1
0
0
Chief Executive Officer
Stock option (right to buy)
7.29
2018-03-12
4
A
0
825000
0.00
A
2028-03-12
Common Stock
825000
825000
D
Ms. Pelletier acquired a vested interest in 66.67% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Commencement Date. The option was awarded in connection with Ms. Pelletier's service as President and Chief Executive Officer.
The option was granted subject to stockholder approval and will be forfeited if stockholder approval is not obtained within twelve months of the date of grant.
/s/ Melanie Ruthrauff Levy, attorney-in-fact
2018-03-14